4PY1 image
Deposition Date 2014-03-25
Release Date 2014-09-03
Last Version Date 2024-11-20
Entry Detail
PDB ID:
4PY1
Keywords:
TRANSFERASE
Title:
Crystal structure of Tyk2 in complex with compound 15, 6-((2,5-dimethoxyphenyl)thio)-3-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Expression System(s):
Escherichia coli
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.16 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 21
4PY1 validation report
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Non-receptor tyrosine-protein kinase TYK2
Gene (Uniprot):TYK2
Mutagens:C936A, Q969A, E971A, K972A, C1142A
Chain IDs:A
Chain Length:318
Number of Molecules:1
Biological Source:Homo sapiens
UniProt ID:P29597 Pfam ID:PF07714 EC:2.7.10.2
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR O-PHOSPHOTYROSINE
Ligand Molecules
2YK
Primary Citation
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Bioorg.Med.Chem.Lett. 24 4132 4140 (2014)
PMID: 25113930 DOI: 10.1016/j.bmcl.2014.07.052

Abstact

Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the structure, potential ligand-protein binding interactions, and pharmacological profiling of potent and highly selective kinase inhibitors based on a triazolopyridazine chemical scaffold.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
4PY1
Feedback Form
Name
Email
Institute
Feedback